APOD and prostate carcinoma: APOD, an oxidative stress response gene increased in ETS+ prostate cancers45, and CD276 (B7-H3), an immune checkpoint associated with adverse prostate cancer outcomes46, were also elevated in cancer cell clusters (Fig. 3b).